<DOC>
	<DOC>NCT00979940</DOC>
	<brief_summary>This research study plans to evaluate the use of atorvastatin in patients with coronary artery disease given immediately before PCI and whether it will decrease the amount of heart damage after PCI.</brief_summary>
	<brief_title>Effects of Short Term, High Dose Atorvastatin Therapy on Periprocedural Myonecrosis and Platelet Inhibition After Percutaneous Coronary Intervention (PCI)</brief_title>
	<detailed_description />
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Atorvastatin Calcium</mesh_term>
	<criteria>patients undergoing revascularization for significant coronary artery disease age range 2185 years nonSTEMI, STEMI cancer renal failure with creatinine&gt;3.0mg/dl liver cirrhosis lymphoproliferative disorder pregnancy thrombocytopenia&lt;150'000 coagulopathy (INR&gt;1.5) abnormal liver function tests illicit drug use history of statin intolerance history of rhabdomyolysis planned use of Glycoprotein IIb/IIIa inhibitors during PCI current therapy with atorvastatin, pravastatin, lovastatin, fluvastatin, or rosuvastatin</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>atorvastatin</keyword>
	<keyword>clopidogrel</keyword>
	<keyword>percutaneous intervention</keyword>
	<keyword>periprocedural myonecrosis</keyword>
</DOC>